Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs

Acquires Swiss Biotech To Expand Neurology Pipeline

Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.

merck kgaa
The Darmstadt-based group is looking for bolt-ons • Source: merck kgaa

It comes as no great surprise that Chord Therapeutics SA, the Swiss biotech which has been looking at the potential of cladribine in rare diseases, has been snapped up by Merck KGaA given that the German group has been been selling an oral version of the well-established chemotherapy as Mavenclad for the treatment of multiple sclerosis for the past few years.

Chord only emerged from stealth in October 2020 with a $16m series A cash injection from healthcare venture capital firm...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.